MKI67 and breast carcinoma: According to the last St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, high Ki67 LI is one of the features indicating increased risk of recurrence in ER-positive, HER2-negative BC, thus indirectly supporting the value of adding chemotherapy to endocrine therapy in such patients [4].